Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Imatib 100 mg


Availability: In stock

Special Price $ 275

BRAND : Imatib 100 mg
STRENGTH : 100 mg
INGREDIENT : Anticancer-Cancer-Treatment-Cipla-Imatinib-Mesylate-100mg-Imatib
COUNT : 100 Tablets

Description of Imatib 100 mg

Brand name: Imatib Generic name: Imatinib mesylate Manufacturer: cipla Strength: 100mg Category: Anti-neoplastic agent Container: 30 tablets in a bottle Product Description: Imatib tablet is an anti cancer medicine which is useful for treating;  Advanced myelogenous leukemia (CML),  Gastrointestinal stromal tumors (GISTs) and a number of malignancies Imatib is a tyrosine kinase inhibitor that prohibits BCR-ABL kinase produced by chromosomal rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia PDG-derived tyrosine kinase that are expressed in gastrointestinal stromal tumor Imatib is used as monotherapy, or it may combine with some other medicine in the conditions of certain types of cancer or bone marrow disorders.

Pharmacology of Imatib 100 mg

Mechanism of action: Imatib contains an active chemical substance known as Imatinib mesylate; it is an inhibitor of certain tyrosine kinase enzymes. Imatib prohibits BCR-ABL tyrosine kinase (atypical enzyme produced by Philadelphia chromosome abnormality in CML) Imatib obstruct the multiplication and promote the apoptosis in BCR-ABL positive cells in addition to fresh leukemia cells from Philadelphia chromosome positive CML Imatib also prohibits tumor growth of BCR-ABL transacted murine myeloid cells along other BCR-ABL positive leukemia CML in blast crisis Pharmacokinetic: Absorption: After an oral administration of Imatib tablets, it is largely absorbed within 2-4 hours. The bioavailability of Imatib tablets is about 98%. Distribution: Imatinib is highly bound to the human plasma protein almost range of 95%. It is mostly bound to albumin and α1-acid glycoprotein. Metabolism: The major enzyme which is essential for metabolism of Imatinib tablet is CYP3A4. Active metabolite of Imatinib is N-demethylated piperizine derivative Excretion: The elimination of Imatinib is predominantly occurred in feces. Nearly 81% of the drug excreted within 7 days through feces and 13% of drug through urine. The half life time of Imatinib and active metabolite N-demethyl derivative (CGP74588) are around 18 and 40 hours respectively

Indication of Imatib 100 mg

Imatib tablets are primarily indicated for the treatment of; Aggressive systemic mastocytosis Chronic esinophillic leukemia Dermatofibrosarcoma protuberans Gastrointestinal stromal tumors Hyperesinophillic syndrome Myelodysplastic syndrome Myeloproliferative disease Philadelphia chromosome positive acute lymphoblastic leukemia Philadelphia chromosome positive chronic myeloid leukemia

Dose & Dosage's of Imatib 100 mg

The prescribed dose of tablet Imatib is 400mg or 600mg as a single dose. Whereas 800mg which is administered as 400mg twice daily. Imatib tablets should be taken with food The recommended dose for following conditions; Acute lymphoblastic leukemia: In adults, the recommended dose is 600mg should be taken orally as a single dose. Myelodysplastic/Myeloproliferative diseases: The prescribed dose is 400mg PO qDay Hyperesinophillic syndrome: In this condition, prescribed dose is 400mg PO qDay Chronic myeloid leukemia: Chronic phase: In newly diagnosed patients, the dose of Imatib tablet is 400mg should be orally taken as a single dose. If chronic phase is failed with the treatment of interferon alpha therapy; dose is increased to 600mg per day. Accelerated phase: 600mg PO qDay; dose should be vary to 400mg PO as twice daily if there is no severe adverse drug reaction or non leukemia associated neutropenia or thrombocytopenia. Dermatofibrosarcoma protuberans: Recommended dose is 400mg PO q12hr Mastocytosis: Without D816V c-kit mutation: 100mg per oral for qDay c-kit mutational status unknown: 400mg per oral qDay ASM related with esinophillic: 100mg PO qDay initially increased to 400mg/day. Gastrointestinal stromal tumors The prescribed dose of the tablet Imatib is 400mg should be taken orally as a twice daily In pediatric: Chronic myeloid leukemia: <1 year: the safety and efficacy of the drug has not been established ≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day Acute lymphoblastic leukemia: <1 year: the safety and efficacy of the drug has not been established ≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day

Side Effects of Imatib 100 mg

Congestive cardiac failure Tachycardia Pulmonary edema Arrhythmia Angina Reynaud’s syndrome Dry skin, alopecia Photosensitivity reactions Abdominal distension Gastro esophageal reflux Ulcer Esophagitis, stomatitis, pancreatitis Weakness, chills, malaise Pancytopenia, Lymphopenia Aplastic anemia Bone marrow depression Febrile neutropenia Hepatitis, jaundice, hepatic failure, hepatic necrosis Angioedema Weight decreased, loss of appetite, dehydration, gout, hyperuricemia, hypocalcaemia, hyperglycemia, hyponatremia, hyperkelamia, hypomagnesemia Joint swelling, muscle stiffness, muscular weakness, arthritis Paresthesia, hypesthesia, syncope, peripheral neuropathy, somnolence, tremor Renal failure, frequency of urine will increased, Hematuria, renal pain Breast enlargement, menorrhagia, sexual dysfunction, gynecomastia, erectile dysfunction, menstruation irregular, nipple pain, scrotal edema Epistaxis, pleural effusion, interstitial pneumonitis, pulmonary fibrosis, pulmonary hypertension, pulmonary hemorrhage

Contraindication of Imatib 100 mg

Hypersensitive reaction to Imatinib mesylate and other excipients present in Imatib tablets

Drug Interaction of Imatib 100 mg

Imatib tablet is contraindicated to some medicines like; Cobimetinib, conivaptan, dihydroergotamine, eliglustat, aspirin, vitamin D, rosuvastatin, duloxetine, dasatinib, grapefruit, ibuprofen, Atorvastatin, pregabalin Missed dose: If patient fail to take Imatib tablet, patient should administered within a time. Otherwise, tablet should be discontinued and follow the next drug schedule.

Precaution of Imatib 100 mg

Caution with use in hepatic impairment patients Avoid combination with strong CYP3A4 inducers Risk of severe CHF or ventricular dysfunction Hemorrhage occurs Growth retardation occurs in children

Usage & Safety profile of Imatib 100 mg Pregnancy & Lactation

Pregnancy category: D Imatib should not recommended to pregnant and breast feeding mothers, it can able to cause fetal malformations and cause fetal harm The metabolites excreted in human milk

Storage of Imatib 100 mg

Imatib tablet container should be stored in cool and dry place It should be keep away from moisture, heat and light